Followers | 23 |
Posts | 2036 |
Boards Moderated | 0 |
Alias Born | 12/06/2017 |
Wednesday, May 11, 2022 7:36:44 AM
When used to treat diabetes, the tech’s pinhead-sized, porous capsules are filled with insulin-producing cells, the company said. In the case of advanced pancreatic cancer treatment, those same capsules are filled with genetically modified cells that behave as a sort of artificial liver.
While PharmaCyte’s system is not a drug delivery system, it does help certain drugs get their job done. When treating pancreatic cancer, the approximately 20,000 live cells that the capsules are filled with convert inactive chemotherapy drugs (ifosfamide) into an active, cancer-killing treatment. The announcement noted that this is exactly what the enzyme system in a person’s natural liver would normally do.
Cell in a Box functionality
Courtesy of PharmaCyte Biotech
Ifosfamide has no effect until it is activated in the liver; therefore, this system could prove particularly useful in limiting the effect of chemotherapy on the body, as it travels through uninfected areas.
The Cell-in-a-Box capsules are placed as close as possible to a patient’s cancerous tumor. Ifosfamide is then given intravenously at a third of the normal dose. That treatment finds its way through the circulatory system to the capsules, where it is then activated directly near the cancer site, the announcement explained.
The company noted that, other than limiting the effect of ifosfamide on the rest of the body, the use of Cell-in-a-Box capsules also helps make the chemotherapy treatment more effective against the cancer. It gets active ifosfamide to the cancerous cells more quickly, which is crucial as the drug has a short half-life.
It also means the full potency of the ifosfamide is concentrated on the cancer, rather than losing potency along the way from the liver to the cancerous tumor. In order to ensure potency, a larger dose of ifosfamide is typically administered. Eliminating the travel time from the liver to the cancerous site means there is less need for such a high dosage. A smaller dosage, in turn, also helps eliminate damage done to the rest of the body.
PharmaCyte claims that “because of the smaller dose, the treatment can be administered without any side effects from the chemotherapy.”
The tech has been tested and found effective in past clinical trials. The Cell-in-a-Box will be used in the way described above for an upcoming Phase IIb clinical trial.
Recent PMCB News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 10:06:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:28 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/04/2023 08:40:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:01:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/31/2023 09:18:17 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM